Jiang, Y.; Fang, X.; Xiang, Y.; Fang, T.; Liu, J.; Lu, K.
Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Curr. Oncol. 2023, 30, 5337-5349.
https://doi.org/10.3390/curroncol30060405
AMA Style
Jiang Y, Fang X, Xiang Y, Fang T, Liu J, Lu K.
Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Current Oncology. 2023; 30(6):5337-5349.
https://doi.org/10.3390/curroncol30060405
Chicago/Turabian Style
Jiang, Yingying, Xiaoxu Fang, Yan Xiang, Tingwen Fang, Jingwen Liu, and Kaihua Lu.
2023. "Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review" Current Oncology 30, no. 6: 5337-5349.
https://doi.org/10.3390/curroncol30060405
APA Style
Jiang, Y., Fang, X., Xiang, Y., Fang, T., Liu, J., & Lu, K.
(2023). Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Current Oncology, 30(6), 5337-5349.
https://doi.org/10.3390/curroncol30060405